Tissue | Expression Dynamics | Abbreviation |
Cervix | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Cervix/USP47_pca_on_diff_genes.png) | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/USP47_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/USP47_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/USP47_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/USP47_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Lung | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Lung/USP47_pca_on_diff_genes.png) | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/USP47_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/USP47_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/USP47_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/USP47_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:001095120 | Skin | AK | negative regulation of endopeptidase activity | 49/1910 | 252/18723 | 6.98e-06 | 1.55e-04 | 49 |
GO:200011724 | Skin | AK | negative regulation of cysteine-type endopeptidase activity | 23/1910 | 86/18723 | 1.13e-05 | 2.36e-04 | 23 |
GO:004315420 | Skin | AK | negative regulation of cysteine-type endopeptidase activity involved in apoptotic process | 21/1910 | 78/18723 | 2.41e-05 | 4.39e-04 | 21 |
GO:003030716 | Skin | AK | positive regulation of cell growth | 34/1910 | 166/18723 | 5.76e-05 | 8.63e-04 | 34 |
GO:19022305 | Skin | AK | negative regulation of intrinsic apoptotic signaling pathway in response to DNA damage | 11/1910 | 29/18723 | 7.32e-05 | 1.05e-03 | 11 |
GO:00457866 | Skin | AK | negative regulation of cell cycle | 63/1910 | 385/18723 | 1.08e-04 | 1.40e-03 | 63 |
GO:004592718 | Skin | AK | positive regulation of growth | 46/1910 | 259/18723 | 1.33e-04 | 1.64e-03 | 46 |
GO:200102020 | Skin | AK | regulation of response to DNA damage stimulus | 40/1910 | 219/18723 | 1.93e-04 | 2.19e-03 | 40 |
GO:00459306 | Skin | AK | negative regulation of mitotic cell cycle | 42/1910 | 235/18723 | 2.21e-04 | 2.46e-03 | 42 |
GO:19019916 | Skin | AK | negative regulation of mitotic cell cycle phase transition | 33/1910 | 179/18723 | 5.67e-04 | 5.06e-03 | 33 |
GO:00346446 | Skin | AK | cellular response to UV | 20/1910 | 90/18723 | 6.22e-04 | 5.45e-03 | 20 |
GO:19019884 | Skin | AK | negative regulation of cell cycle phase transition | 42/1910 | 249/18723 | 7.65e-04 | 6.39e-03 | 42 |
GO:00094116 | Skin | AK | response to UV | 28/1910 | 149/18723 | 1.05e-03 | 8.24e-03 | 28 |
GO:20010215 | Skin | AK | negative regulation of response to DNA damage stimulus | 18/1910 | 81/18723 | 1.14e-03 | 8.81e-03 | 18 |
GO:00000865 | Skin | AK | G2/M transition of mitotic cell cycle | 26/1910 | 137/18723 | 1.35e-03 | 1.00e-02 | 26 |
GO:000941025 | Skin | AK | response to xenobiotic stimulus | 67/1910 | 462/18723 | 1.98e-03 | 1.34e-02 | 67 |
GO:00448395 | Skin | AK | cell cycle G2/M phase transition | 27/1910 | 148/18723 | 2.01e-03 | 1.35e-02 | 27 |
GO:00109485 | Skin | AK | negative regulation of cell cycle process | 45/1910 | 294/18723 | 3.73e-03 | 2.22e-02 | 45 |
GO:00094166 | Skin | AK | response to light stimulus | 48/1910 | 320/18723 | 4.20e-03 | 2.45e-02 | 48 |
GO:00714822 | Skin | AK | cellular response to light stimulus | 22/1910 | 123/18723 | 6.33e-03 | 3.38e-02 | 22 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
USP47 | SNV | Missense_Mutation | rs754155092 | c.2314N>T | p.Arg772Cys | p.R772C | Q96K76 | protein_coding | deleterious(0) | probably_damaging(0.965) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
USP47 | SNV | Missense_Mutation | | c.3127N>C | p.Glu1043Gln | p.E1043Q | Q96K76 | protein_coding | tolerated(0.25) | benign(0.047) | TCGA-AR-A0U0-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
USP47 | SNV | Missense_Mutation | novel | c.81N>C | p.Met27Ile | p.M27I | Q96K76 | protein_coding | tolerated_low_confidence(0.19) | benign(0) | TCGA-BH-A0B6-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
USP47 | SNV | Missense_Mutation | | c.4046G>A | p.Arg1349His | p.R1349H | Q96K76 | protein_coding | tolerated(0.09) | benign(0) | TCGA-BH-A18F-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxotere | CR |
USP47 | SNV | Missense_Mutation | | c.3865C>T | p.His1289Tyr | p.H1289Y | Q96K76 | protein_coding | deleterious(0.01) | benign(0.101) | TCGA-C8-A12Q-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | PD |
USP47 | SNV | Missense_Mutation | | c.2879N>G | p.Asp960Gly | p.D960G | Q96K76 | protein_coding | tolerated(0.06) | probably_damaging(0.971) | TCGA-D8-A27I-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | adrimycin+cyclophosphamide | SD |
USP47 | SNV | Missense_Mutation | | c.1726N>C | p.Asp576His | p.D576H | Q96K76 | protein_coding | tolerated(0.1) | benign(0) | TCGA-EW-A1P4-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | docetaxel | SD |
USP47 | SNV | Missense_Mutation | novel | c.3742G>C | p.Glu1248Gln | p.E1248Q | Q96K76 | protein_coding | deleterious(0.04) | probably_damaging(0.954) | TCGA-LD-A74U-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | taxotere | SD |
USP47 | insertion | Frame_Shift_Ins | novel | c.3125_3126insGTCCCTC | p.Asp1042GlufsTer4 | p.D1042Efs*4 | Q96K76 | protein_coding | | | TCGA-AR-A0U0-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
USP47 | SNV | Missense_Mutation | novel | c.1153N>A | p.Leu385Met | p.L385M | Q96K76 | protein_coding | deleterious(0) | probably_damaging(0.996) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |